Pentostatin and Rituximab in the Treatment of Patients With B-Cell Malignancies
June 1st 2000Both pentostatin (Nipent) and rituximab (Rituxan) have single-agent activity in B-cell malignancies, including indolent and intermediate-grade non-Hodgkin’s lymphoma (NHL). Pentostatin is also active in pretreated patients